bioengineer.org /1 month ago

Rare EGFR mutation sharply raises lung cancer risk in large genetic study

An observational study of 3.3 million research participants found that inherited EGFR T790M was associated with 25-fold higher lung cancer risk overall and more than 60-fold risk a...

Read source
bioengineer.org /3 weeks ago

Rare EGFR Mutation Shows Primary Resistance to Afatinib in Lung Cancer Case

A case report documents rapid progression and death in a lung cancer patient with a rare EGFR PACC mutation who showed primary resistance to afatinib.

Read source
journals.plos.org /3 days ago

GPCR-Gαq signaling drives adaptive resistance to MEK inhibition in BRAF-mutant melanoma

by Jingyi Ke, Zi Wang, Zhengyang Guo, Guangshuo Ou, Wei Li Oncogenic BRAFV600E mutations drive constitutive MAPK signaling across various cancers; however, resistance to MEK inhib...

Read source
bioengineer.org /1 week ago

Patient Survived Twenty Months After Small-Cell Transformation of Resected Lung Adenocarcinoma

A clinical case report documents a 48-year-old woman with EGFR-mutant lung adenocarcinoma who developed small-cell lung cancer transformation four years after surgery and survived...

Read source
bioengineer.org /1 week ago

Meta-Analysis Assesses Targeted Therapies for MET-Altered Non-Small Cell Lung Cancer

A systematic review and meta-analysis of 25 clinical trials found that MET tyrosine kinase inhibitors achieved a 49 percent objective response rate in MET-altered non-small cell lu...

Read source
qchron.com /4 weeks ago

RYBREVANT FASPROâ„¢ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-lin...

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line P...

Read source
qchron.com /4 weeks ago

New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-muta...

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G1...

Read source
healio.com /2 weeks ago

Zanidatamab regimens improve survival for gastroesophageal cancer

First-line zanidatamab-hrii plus chemotherapy, without or with tislelizumab-jsgr, extended survival 24% and 35% vs. trastuzumab plus chemotherapy for those with locally advanced or...

Read source
aacr.org /1 month ago

HER2-targeted Therapy for Salivary Gland Cancer

Salivary gland cancer is rare, and there are no standard treatments for advanced-stage disease. Recent research supports the use of HER2-targeted therapy for patients with metastat...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.